CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corvus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$9.65+0.13 (+1.37%)
Close on Oct 19, 2026
- Market cap
- $891.35M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Corvus Pharmaceuticals has not reported a dividend
No dividend per share appears in Corvus Pharmaceuticals's annual filings since fiscal 2014.